مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

9
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

8
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma

Pages

  376-383

Abstract

 Background: Activating mutations in the Epidermal growth factor receptor (EGFR) are initially responsive to tyrosine kinase inhibitors (TKIs), but responses to TKIs is not permanent and drug resistance eventually happens for almost all patients. Subsequent studies found different resistance mechanisms, among which (EGFR) T790M mutation is the most important mechanism of TKI treatment failure. Using cell-free DNA (cfDNA) is a new way for diagnosing resistance mutations in EGFR. The aim of present study is to determine cfDNAidentified recurrence mutation rate and their association with clinical outcome in lung Adenocarcinoma patients. Materials and Methods: Patients who were diagnosed with metastatic adenocarcinoma of the lung and acquired resistance to TKIs were enrolled. The incidence of T790M positivity, overall survival (OS) and median duration of TKI treatment before progression was calculated. Polymerase chain reaction (PCR) and sequencing were used to identify the T790M mutation in cfDNA. Results: The incidence of T790M mutations was higher in men, younger cases (<59 years), in patients with L858R primary mutation and never smokers although they were not significantly different (P-values= 041, 0. 316, 0. 316 and 0. 158, respectively). There was significant longer OS in the Del19 subgroup than the L858R subgroup (p = 0. 014). In multivariable analysis, significant longer OS was associated with younger age (<59 years) and primary EGFR mutation exon 19 (P-values= 0. 028 and 0. 050, respectively). Conclusion: T790M mutations frequency may differ by ethnicity, genetic factors and EGFR primary mutations. Detecting T790M mutations in plasma is considered as an indicator of treatment with third generation EGFR-TKIs.

Cites

  • No record.
  • References

  • No record.
  • Cite

    APA: Copy

    MIRTAVOOS MAHYARI, HANIFEH, ABBASI DEZFOULI, AZIZOLLAH, ESFAHANI MONFARED, ZAHRA, KHOSRAVI, ADNAN, SEIFI, SHARAREH, & SHEIKHY, KAMBIZ. (2022). T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma. TANAFFOS, 21(3), 376-383. SID. https://sid.ir/paper/1078863/en

    Vancouver: Copy

    MIRTAVOOS MAHYARI HANIFEH, ABBASI DEZFOULI AZIZOLLAH, ESFAHANI MONFARED ZAHRA, KHOSRAVI ADNAN, SEIFI SHARAREH, SHEIKHY KAMBIZ. T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma. TANAFFOS[Internet]. 2022;21(3):376-383. Available from: https://sid.ir/paper/1078863/en

    IEEE: Copy

    HANIFEH MIRTAVOOS MAHYARI, AZIZOLLAH ABBASI DEZFOULI, ZAHRA ESFAHANI MONFARED, ADNAN KHOSRAVI, SHARAREH SEIFI, and KAMBIZ SHEIKHY, “T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma,” TANAFFOS, vol. 21, no. 3, pp. 376–383, 2022, [Online]. Available: https://sid.ir/paper/1078863/en

    Related Journal Papers

  • No record.
  • Related Seminar Papers

  • No record.
  • Related Plans

  • No record.
  • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button